Marksans Pharma Limited

BSE: 524404 NSE: MARKSANS
Marksans Pharma Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24110MH1992PLC066364 Incorporated 16 April 1992 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: MARKSANS · BSE: 524404 Public Limited Company pharma
Data last updated
Market Cap
₹13,993 Cr
MARKSANS · NSE
Share Price
₹308.75
+1.65% today
Revenue
₹2,951 Cr
FY 2025-26 · +12.5% YoY
EBITDA
₹601 Cr
Margin 20.4%
Net Profit
₹416 Cr
FY 2025-26 · +9.7% YoY
P/E (TTM)
24.6x
P/B 4.1x
ROE
15.3%
ROCE 19.0%
Debt / Equity
0.12
Interest cover 4.8x

About Marksans Pharma Limited

Data last updated:

Marksans Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 16 April 1992 and has been in existence for over 34 years.

Its director Mark Saldanha is #498 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24110MH1992PLC066364. It is a listed company as per MCA records. Its shares are listed on BSE: 524404 and NSE: MARKSANS.

The company has an authorised share capital of ₹69 Cr and a paid-up capital of ₹45.32 Cr. It was formerly known as Tasc Pharmaceuticals Limited and Tasc Industries (India) Limited. It is led by directors including Mark Saldanha (Managing Director) and Sandra Saldanha (Whole-Time Director).

Its last annual general meeting (AGM) was held on 27 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 11th Floor Grandeur Veera Desai Extension Road Oshiwara Andheri (W), Mumbai, Maharashtra, India – 400053.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,950.94 Cr, a growth of 12.5% compared to the previous year. For the same year it recorded a net profit of ₹416.43 Cr (net margin 14.1%) and EBITDA of ₹600.78 Cr (EBITDA margin 20.4%). The net worth stands at ₹3,023.16 Cr (up 22.5% YoY). Total assets are valued at ₹3,401.97 Cr (up 20.8% YoY).

The company has about 95 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Marksans Pharma. As per MCA filings, the company has open charges of ₹226 Cr and satisfied charges of ₹337.16 Cr on record. Court records list 17 cases involving the company, including 6 filed by the company and 11 filed against it.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website marksanspharma.com.

Company details

CIN L24110MH1992PLC066364
Registration Number 066364
Incorporation Date 16 April 1992
ROC Mumbai
Listing Status Listed - Listed on NSE (MARKSANS); Listed on BSE (524404)
Company Status Active
Date of Last AGM 27 August 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Marksans Pharma has undergone 2 name changes throughout its history. The company was previously known as Tasc Pharmaceuticals Limited, and Tasc Industries (India) Limited. The current legal name is Marksans Pharma Limited.

Company NameStatus
Marksans Pharma LimitedCurrent
Tasc Pharmaceuticals LimitedPrevious
Tasc Industries (India) LimitedPrevious
Key People
Mark Saldanha Managing Director Sandra Saldanha Whole-Time Director Varddhman Vikramaditya Jain Whole-Time Director

Recognitions & Rankings of Marksans Pharma

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#368
Valuation
₹15,060 Cr
India's Richest People 2026 edition · 1 director · Source: Hurun India

Contact details

Marksans Pharma Limited's registered office is in Mumbai, Maharashtra. Its website is marksanspharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    marksanspharma.com
  • Social Media
  • Registered Address
    11th Floor Grandeur Veera Desai Extension Road Oshiwara Andheri (W), Mumbai, Maharashtra, India – 400053
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Marksans Pharma Limited, buy the company report.

Comprehensive company report
Marksans Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Marksans Pharma operates one associated brand: Marksans Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Marksans Pharma
Pharmaceutical drug formulations are manufactured, developed, and marketed.marksanspharma.com

Business activity

The main business activity of Marksans Pharma is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Marksans Pharma Limited, buy the company report.

Financials of Marksans Pharma Limited

FY 2025-26 filings available

Marksans Pharma Limited reported revenue of ₹2,950.94 Cr (up 12.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,951 Cr
+12.5% YoY
EBITDA
₹601 Cr
+12.8% YoY
Profit After Tax
₹416 Cr
+9.7% YoY
Net Worth
₹3,023 Cr
+22.5% YoY
Total Assets
₹3,402 Cr
+20.8% YoY
Total Debt
₹343 Cr
+6.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,9512,6232,1771,8521,4911,3761,134
Revenue growth+12.5%+20.5%+17.6%+24.2%+8.3%+21.3%-
EBITDA601533459339259340192
EBITDA margin+20.4%+20.3%+21.1%+18.3%+17.4%+24.7%+17.0%
Profit before tax561504424338248302157
Net profit416380314267185236121
Net profit margin+14.1%+14.5%+14.4%+14.4%+12.4%+17.1%+10.6%
EPS (₹)9.228.406.925.884.515.762.95
Balance sheet
Total assets3,4022,8172,3351,8911,336947685
Net worth3,0232,4672,0651,7451,202886636
Total debt34332224412311134.1029.65
Cash & bank99070467471534921293.73
Net working capital2,2691,7851,5001,391914628387
Cash flow
Cash from operations45820723023799.26179233
Cash from investing(249)(49.01)(141)(259)(84.39)(44.85)(59.58)
Cash from financing(70.93)(65.15)(68.73)19879.51(15.29)(114)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue940841856754720620708682
Revenue growth (YoY)+30.5%+35.6%+20.8%+10.6%+12.2%+5.0%--
Other income18.1525.4035.1720.1421.575.6415.3427.85
EBITDA214213195161144100127139
EBITDA margin+22.8%+25.3%+22.8%+21.3%+20.1%+16.1%+17.9%+20.4%
Depreciation32.1124.8624.2924.3326.9223.1022.7420.69
Interest6.837.006.315.945.826.073.442.67
Profit before tax19420720015113376.59116143
Tax49.9847.1650.9736.9434.2018.4025.3738.19
Net profit14415914911499.1258.1990.73105
EPS (₹)3.113.473.272.502.171.292.002.31
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3411,174853655658600433
Revenue growth+14.2%+37.6%+30.2%-0.5%+9.8%+38.3%-
EBITDA32420814091.9011411471.50
EBITDA margin+24.1%+17.7%+16.4%+14.0%+17.3%+19.0%+16.5%
Profit before tax39224317213213412452.74
Net profit29918713410310498.3737.88
Net profit margin+22.3%+16.0%+15.7%+15.7%+15.8%+16.4%+8.7%
EPS (₹)6.644.152.952.272.542.400.93
Balance sheet
Total assets1,6701,4001,2351,122801621523
Net worth1,6521,3831,2231,111785600506
Total debt12.1310.848.137.6914.3114.3710.81
Cash & bank4472693124402241063.35
Net working capital1,002738649699434260178
Cash flow
Cash from operations21131.0234.0551.7355.97107108
Cash from investing(141)17.24(114)(195)(128)8.87(24.15)
Cash from financing(39.23)(29.92)(26.22)21070.86(13.53)(81.87)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue314321362340320320299312
Revenue growth (YoY)-2.1%+0.5%+20.8%+8.9%+3.8%+25.6%--
Other income57.2417.4727.4815.8658.192.016.6422.51
Total expenses261239256264248250248252
EBITDA52.3582.1110675.4572.0770.0551.7659.94
EBITDA margin+16.7%+25.6%+29.3%+22.2%+22.5%+21.9%+17.3%+19.2%
Depreciation9.058.788.768.838.468.198.187.42
Interest0.340.340.350.360.320.300.310.30
Profit before tax10090.4612482.1212163.5749.9174.73
Tax14.6721.4232.4421.2121.6915.5212.3119.26

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue940841856754720620708682
Revenue growth (YoY)+30.5%+35.6%+20.8%+10.6%+12.2%+5.0%--
Other income18.1525.4035.1720.1421.575.6415.3427.85
EBITDA214213195161144100127139
EBITDA margin+22.8%+25.3%+22.8%+21.3%+20.1%+16.1%+17.9%+20.4%
Depreciation32.1124.8624.2924.3326.9223.1022.7420.69
Interest6.837.006.315.945.826.073.442.67
Profit before tax19420720015113376.59116143
Tax49.9847.1650.9736.9434.2018.4025.3738.19
Net profit14415914911499.1258.1990.73105
EPS (₹)3.113.473.272.502.171.292.002.31
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,9512,6232,1771,8521,4911,3761,134
Revenue growth+12.5%+20.5%+17.6%+24.2%+8.3%+21.3%-
Other income82.5366.3350.4259.3141.856.690.33
Total expenses2,3502,0901,7191,5131,2321,037942
Employee cost421350294239220197168
EBITDA601533459339259340192
EBITDA margin+20.4%+20.3%+21.1%+18.3%+17.4%+24.7%+17.0%
Depreciation98.6383.3974.2751.8544.7836.1526.66
Interest24.1311.6611.209.138.457.998.75
Profit before tax561504424338248302157
Tax14012110972.3360.7063.6236.42
Net profit416380314267185236121
Net profit margin+14.1%+14.5%+14.4%+14.4%+12.4%+17.1%+10.6%
EPS (₹)9.228.406.925.884.515.762.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital45.3245.3245.3245.3240.9340.9340.93
Reserves & surplus2,9782,4222,0201,7001,068846595
Shareholders' funds (net worth)3,0232,4672,0651,7451,202886636
Minority interest29.5222.4720.8519.9120.7018.8613.11
Secured loans29.5923.0929.0941.5941.2918.7418.89
Unsecured loans31429921581.3669.4915.3610.76
Total debt34332224412311134.1029.65
Total liabilities3,4022,8172,3351,8911,336947685
Assets
Gross block1,6051,4131,193828726552563
Net block1,044982776486428309303
Capital work in progress58.5827.119.429.872.5711.680.00
Investments0.000.7426.990.540.440.260.00
Inventories972846618485424404242
Sundry debtors645540453417395272243
Cash & bank balances99070467471534921293.73
Loans & advances11611490.8058.2232.2814.1114.66
Total current assets2,7232,2031,8361,6751,201903594
Total current liabilities454419336284287274207
Net working capital2,2691,7851,5001,391914628387
Total assets3,4022,8172,3351,8911,336947685
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash49640338220611293.7333.54
Net cash from operating activities45820723023799.26179233
Net cash from investing activities(249)(49.01)(141)(259)(84.39)(44.85)(59.58)
Net cash from financing activities(70.93)(65.15)(68.73)19879.51(15.29)(114)
Net change in cash13892.5120.8417694.3811860.19
Closing cash99070467471534921293.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.5%+20.5%+17.6%+24.2%+8.3%+21.3%-
EBITDA growth+12.8%+16.2%+35.2%+31.1%-23.8%+76.7%-
PBT growth+11.2%+19.0%+25.4%+36.4%-18.1%+92.3%+50.7%
Net income growth+9.7%+21.1%+17.7%+44.4%-21.8%+95.4%-
Revenue CAGR (3Y)+16.8%+20.7%+16.5%+17.8%+14.2%+14.7%+13.9%
EBITDA CAGR (3Y)+21.0%+27.2%+10.5%+20.9%+25.1%+63.0%+62.6%
Profitability & leverage
Net income margin+14.2%+14.6%+14.5%+14.3%+12.5%+17.3%+10.7%
Return on capital employed+19.0%+20.2%+20.8%+21.8%+22.8%+38.8%+25.0%
Return on net worth+15.3%+16.9%+16.5%+18.0%+17.9%+31.3%+20.5%
Debt / equity0.120.120.100.080.070.040.11
Long-term debt / equity0.100.100.070.040.020.010.01
Interest cover4.812.602.913.183.952.635.28
Efficiency & per share
Fixed asset turnover1.962.012.152.382.332.472.12
Inventory turnover3.253.583.954.073.604.264.24
Debtors turnover4.985.285.014.564.475.345.40
EPS (₹)9.228.406.925.884.515.762.95
Dividend per share (₹)0.900.800.600.500.250.250.10
Book value per share (₹)66.7154.4445.5738.5127.1021.6615.54
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue314321362340320320299312
Revenue growth (YoY)-2.1%+0.5%+20.8%+8.9%+3.8%+25.6%--
Other income57.2417.4727.4815.8658.192.016.6422.51
Total expenses261239256264248250248252
EBITDA52.3582.1110675.4572.0770.0551.7659.94
EBITDA margin+16.7%+25.6%+29.3%+22.2%+22.5%+21.9%+17.3%+19.2%
Depreciation9.058.788.768.838.468.198.187.42
Interest0.340.340.350.360.320.300.310.30
Profit before tax10090.4612482.1212163.5749.9174.73
Tax14.6721.4232.4421.2121.6915.5212.3119.26
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3411,174853655658600433
Revenue growth+14.2%+37.6%+30.2%-0.5%+9.8%+38.3%-
Other income10465.7962.0760.4842.2531.160.17
Total expenses1,018966713563545486362
Employee cost12210277.1956.0960.4654.6448.51
EBITDA32420814091.9011411471.50
EBITDA margin+24.1%+17.7%+16.4%+14.0%+17.3%+19.0%+16.5%
Depreciation34.2329.4529.1316.7417.6615.1911.64
Interest1.331.170.993.613.805.357.29
Profit before tax39224317213213412452.74
Tax90.8454.9838.1429.1730.5225.9514.83
Net profit29918713410310498.3737.88
Net profit margin+22.3%+16.0%+15.7%+15.7%+15.8%+16.4%+8.7%
EPS (₹)6.644.152.952.272.542.400.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital45.3245.3245.3245.3240.9340.9340.93
Reserves & surplus1,6071,3381,1771,066651559465
Shareholders' funds (net worth)1,6521,3831,2231,111785600506
Secured loans0.000.000.000.000.000.000.05
Unsecured loans12.1310.848.137.6914.3114.3710.76
Total debt12.1310.848.137.6914.3114.3710.81
Total liabilities1,6701,4001,2351,122801621523
Assets
Gross block603555421319301277247
Net block398383272144136129115
Capital work in progress0.000.000.003.910.000.000.00
Investments267266293266237236236
Inventories18920519113110493.6974.60
Sundry debtors623550370305247169162
Cash & bank balances4472693124402241063.35
Loans & advances49.7358.0047.4636.5214.922.894.23
Total current assets1,3091,081921913589371244
Total current liabilities30734327121415611166.08
Net working capital1,002738649699434260178
Total assets1,6701,4001,2351,122801621523
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash60.2741.9314881.1982.423.351.80
Net cash from operating activities21131.0234.0551.7355.97107108
Net cash from investing activities(141)17.24(114)(195)(128)8.87(24.15)
Net cash from financing activities(39.23)(29.92)(26.22)21070.86(13.53)(81.87)
Net change in cash30.9818.34(106)67.12(1.23)1021.55
Closing cash4472693124402241063.35
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.2%+37.6%+30.2%-0.5%+9.8%+38.3%-
EBITDA growth+55.5%+48.7%+52.3%-19.2%-0.0%+59.1%-
PBT growth+61.0%+41.5%+30.2%-1.8%+8.2%+135.8%-5.8%
Net income growth+59.6%+40.2%+29.9%-1.0%+5.7%+159.7%-
Revenue CAGR (3Y)+27.0%+21.3%+12.5%+14.8%+15.8%+26.7%+26.2%
EBITDA CAGR (3Y)+52.1%+22.3%+7.2%+8.7%+21.5%+57.5%+42.9%
Profitability & leverage
Net income margin+22.4%+16.0%+15.7%+15.7%+15.8%+16.4%+8.8%
Return on capital employed+25.6%+18.6%+14.7%+14.1%+19.5%+22.0%+10.2%
Return on net worth+19.8%+14.5%+11.5%+10.9%+15.0%+17.3%+7.1%
Debt / equity0.010.010.010.010.020.020.09
Long-term debt / equity0.010.010.010.000.010.010.01
Interest cover0.460.650.894.803.965.4312.18
Efficiency & per share
Fixed asset turnover2.322.412.312.112.282.291.84
Inventory turnover6.805.935.305.586.677.135.98
Debtors turnover2.292.552.532.373.173.622.55
EPS (₹)6.644.152.952.272.542.400.93
Dividend per share (₹)0.900.800.600.500.250.250.10
Book value per share (₹)36.4630.5326.9824.5216.9014.6512.35

To see the full year-wise statements and ratios of Marksans Pharma Limited, buy the company report.

Board of directors of Marksans Pharma Limited

Marksans Pharma has 8 current directors and 11 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sandra SaldanhaWhole-Time Director25 Sep 201412 Years 1 MonthsCurrent
Varddhman Vikramaditya JainWhole-Time Director24 Jan 20197 Years 9 MonthsCurrent
Abhinna Mohanty Sundar
Also directs: Rytus Healthcare Private Limited, SSB Seva Kartavya Private Limited
Director11 Jul 20197 Years 3 MonthsCurrent
Mark SaldanhaManaging Director06 Oct 201511 Years 1 MonthsCurrent
Digant Mahesh Parikh
Also directs: Rossell India Limited, Rossell Techsys Limited, Akansha Consultancy Services Limited
Director14 Mar 20188 Years 7 MonthsCurrent
Sunny Sharma
Also directs: Advanced Enzyme Technologies Limited, Lattice Medtech Private Limited, Arcatron Mobility Private Limited and 5 more
Director11 Aug 20215 Years 2 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Marksans Pharma Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Marksans Pharma Limitedthis company₹2,950.94 Cr (FY 2026)₹416.43 Cr14.1%12.5%95Mumbai, Maharashtra, India
Eris Lifesciences Limited₹2,912 Cr (FY 2025)43.0%Ahmedabad, Gujarat, India
Pfizer Limited₹2,453.6 Cr (FY 2025)3.0%Mumbai, Maharashtra, India
FDC Limited₹2,198.78 Cr (FY 2025)8.0%Mumbai, Maharashtra, India
Unichem Laboratories Limited₹2,146.29 Cr (FY 2025)18.0%Mumbai, Maharashtra, India
Caplin Point Laboratories Limited₹2,033.9 Cr (FY 2025)15.0%Chennai, Tamil Nadu, India

To see the full peer comparison of Marksans Pharma Limited, buy the company report.

Auditor

Marksans Pharma Limited is audited by M S K A & Associates for the financial year 2024.

Auditor firmFinancial yearFirm registration number
M S K A & AssociatesFY 2024105047W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 43.90%, foreign institutional investors hold 17.50%, domestic institutional investors hold 6.20% and retail and other public shareholders hold 32.50%.

Promoters: 43.90%DII (Domestic Institutional): 6.20%FII (Foreign Institutional): 17.50%Retail & Others: 32.50%
Sep 2026
QUARTER
43.90% Promoters
6.20% DII (Domestic Institutional)
17.50% FII (Foreign Institutional)
32.50% Retail & Others
Promoter holding - history
Now 43.90% · Sep 2026High 43.90% · Dec 2025Low 43.90% · Dec 2025
42%42.8%43.5%44.3%45%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 43.90%Mar 2026: 43.90%Jun 2026: 43.90%Sep 2026: 43.90%43.90%43.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters43.90%43.90%43.90%43.90%
Public56.10%56.10%56.10%56.10%

Charges & borrowings

Open charges
₹226 Cr
Satisfied charges
₹337.16 Cr
Breakdown by lending institutions
State Bank of India₹226.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
07 Feb 200680034914State Bank of India₹226 CrOpen
07 Sep 2017100125187State Bank of India₹66.8 CrSatisfied
23 Jun 201510604294State Bank of India₹44.41 CrSatisfied
23 Dec 201310471042Bank of India₹4 CrSatisfied
13 Aug 201010241328Bank of India₹6 CrSatisfied

To see the full charge records of Marksans Pharma Limited, buy the company report.

Total charge records: 26 View all charges

Credit ratings & regulatory alerts

Marksans Pharma Limited was last rated by Indiarating on 29 Jun 2021.

Rating agencyRated onRating
Indiarating29 Jun 2021

To see the full credit ratings and regulatory alerts of Marksans Pharma Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Marksans Pharma Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Marksans Pharma Limited has a workforce of 95 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.

Employee count
95
Active EPFO establishments
1
Employee growth
13.1%

GST

No GST registration is on our record for Marksans Pharma Limited; the GSTIN and return-filing check is in the company report Buy the company report.

Recent activity

Marksans Pharma Limited has 29 board changes on record since 2005: 19 appointments and 10 cessations. The latest: Seetharama Raju Buddharaju ceased to be Director on 01 Apr 2025.

AGM
Marksans Pharma Limited last Annual general meeting of members was held on 27 Aug 2026 as per latest MCA records.
Filing
Marksans Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Ceased
Seetharama Raju Buddharaju ceased to be Director.
Appointed
Srinivas Mishra was appointed as Director.
Charges
A charge with State Bank Of India of Rs. 226.00 Cr registered on 07 Feb 2006 with Charge ID 80034914 was modified on 03 Feb 2025.
Ceased
Meena Rani Surana ceased to be Director.
Appointed
Shailaja Vardhan was appointed as Director.
Charges
A charge registered on 07 Sep 2017 via Charge ID 100125187 with State Bank Of India was fully satisfied on 29 Oct 2021.
Appointed
Sunny Sharma was appointed as Director.
Appointed
Meena Rani Surana was appointed as Director.
Appointed
Abhinna Mohanty Sundar was appointed as Director.
Ceased
Ajoy Joshi ceased to be Director.

85 earlier events are in the company report.

News

MARKSANS: Q2 CONS NET PROFIT 1.41B RUPEES VS 983M (YOY)
04 Nov 2026 · Exchange Update
MARKSANS: Q2 REVENUE 9.4B RUPEES VS 7.2B (YOY)
04 Nov 2026 · Exchange Update
MARKSANS: Q2 EBITDA 2.14B RUPEES VS 1.4B (YOY); Q2 EBITDA MARGIN 22.8% VS 20.04%
04 Nov 2026 · Exchange Update

Frequently asked questions

Marksans Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 16 April 1992 (34+ years old) and is registered under CIN L24110MH1992PLC066364. Listed on BSE: 524404 and NSE: MARKSANS.

Marksans Pharma reported revenue of ₹2,950.94 Cr for FY 2025-26 (up 12.5% YoY) based on consolidated financials.

Marksans Pharma has 8 current directors:

The latest financial statements of Marksans Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 27 August 2026. Year-wise statements from 2015 are in the company report.

The CIN (Corporate Identification Number) of Marksans Pharma is L24110MH1992PLC066364. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Marksans Pharma is a listed company as per MCA records. Its shares are listed on both BSE (code: 524404) and NSE (symbol: MARKSANS).

Marksans Pharma has 17 court cases on record: 6 filed by the company and 11 filed against it. Most are in the high courts.

Marksans Pharma was incorporated on 16 April 1992, making it 34+ years old. It is registered with the Registrar of Companies, Mumbai.

The peers of Marksans Pharma by revenue are Eris Lifesciences Limited, Pfizer Limited, FDC Limited, Unichem Laboratories Limited, Caplin Point Laboratories Limited, all in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).

Seetharama Raju Buddharaju ceased to be Director on 01 Apr 2025. Srinivas Mishra was appointed as Director on 01 Apr 2025. Meena Rani Surana ceased to be Director on 30 May 2023. Marksans Pharma has 29 board changes on record in total.

Marksans Pharma can be reached through the website marksanspharma.com. Its registered office is in Mumbai, Maharashtra, India.